Investing in Groundbreaking Mass Spectrometry Technology Allows Contract
Research Organization to Offer Pharmaceutical Clients Comprehensive
Pre-Clinical Study Data
MILFORD, Mass., Feb. 16 /PRNewswire-FirstCall/ -- Waters Corporation
(NYSE: WAT) announced today that XenoTech (Lenexa, KS) has begun offering new
metabolite profiling services made possible in part by its recent acquisition
of a Waters(R) Synapt(TM) High Definition Mass Spectrometry(TM) (HDMS) System.
The Synapt HDMS System is the centerpiece of its metabolite profiling efforts
and allows XenoTech to offer one-of-a-kind services to companies that are
investigating promising new drug candidates. Integrated with a Waters
ACQUITY(R) UltraPerformance Liquid Chromatograph (UPLC(R)) the Synapt HDMS
System will provide XenoTech's scientific consultants with in vitro drug
metabolism study data to support its clients' drug discovery decision-making
process, offering them insights into the viability of potential drug
candidates prior to their introduction into clinical trials.
"We have built a high degree of quality into XenoTech's products and in
vitro services," states Andrew Parkinson, CEO / CSO of XenoTech. "We enjoy a
very strong reputation for drug metabolism research and for our consultative
approach to contract services. Our customers know that they can expect the
best from us, and in turn, we expect the best from the instrumentation that we
use to investigate their compounds"
"The economic landscape comes into play as well," says Parkinson.
"Customers are faced with the need to collect more information on their
developmental drugs with limited budgets and reduced staff. As a provider of
contract services, we must produce the most meaningful and reliable data as
quickly and efficiently as possible using small amounts of costly test
compounds, and offer flexibility in our study designs to achieve cost savings
and provide value for money. The Waters Synapt HDMS System was a perfect fit
for both our scientific expectations and our operational requirements."
XenoTech purchased the Waters Synapt HDMS System after an exhaustive
six-month evaluation of the offerings of all commercial instrument providers.
"We needed flawless high resolution and accurate mass," said Paul Toren,
Director of Drug Metabolism and Analytical Chemistry at XenoTech. "We were
impressed with the integrated software and work-flow, and once we saw the
added capabilities of the Synapt HDMS's ion mobility feature, we were
convinced that this was the instrument for XenoTech's lab."
Metabolic profiling is an important and growing area of expertise for
XenoTech. Its unique system of in vitro metabolite profiling can alleviate the
need for expensive and time-consuming pre-clinical animal studies. XenoTech's
scientists screen promising drug compounds by exposing them to
drug-metabolizing enzymes derived from human liver cells, or hepatocytes.
XenoTech monitors the production of metabolites that might prove toxic or
interfere with the intended action of the compound or co-administered
pharmaceuticals. These studies give clients an early indication whether their
drug candidate could cause adverse consequences in vivo. XenoTech is relying
on the sensitivity and the ability of the Waters Synapt HDMS to identify drug
metabolites, as recommended by the FDA, and to provide its scientific
consultants with reliable and comprehensive scientific data to make sound
recommendations for their clients.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) creates business advantage for
laboratory-dependent organizations by delivering practical and sustainable
innovation to enable significant advancements in such areas as healthcare
delivery, environmental management, food safety, and water quality worldwide.
Pioneering a connected portfolio of separations science, laboratory
information management, mass spectrometry and thermal analysis, Waters
technology breakthroughs and laboratory solutions provide an enduring platform
for customer success.
With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is
driving scientific discovery and operational excellence for customers
About XenoTech LLC (www.xenotechllc.com)
XenoTech is a Contract Research Organization (CRO) serving clients with
unparalleled experience and expertise in evaluating drug candidates as
substrates, inhibitors and inducers of cytochrome P450 enzymes. The company
offers a variety of in vitro contract studies for drug candidate evaluation,
as well as an extensive selection of products for drug metabolism research.
XenoTech is a subsidiary of Sekisui Chemical Co., Ltd. The company was founded
in 1994 by Dr. Andrew Parkinson.
Waters, High Definition Mass Spectrometry, ACQUITY, and Synapt are
trademarks of Waters Corporation.
Media Contacts Waters Corporation
:Brian J. Murphy